MedTrace Logo

A Rheumatoid Arthritis Study in Participants

NCT01202760 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1004

Last updated 2018-04-25

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis with or without background disease-modifying anti-rheumatic drug (DMARD) therapy.

This study is comprised of 2 periods:

Period 1 - 24-week blinded treatment

Period 2 - 48-week post-treatment follow-up

Conditions

Interventions

DRUG

LY2127399

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-12-31
Completion
2013-07-31

Countries

  • United States
  • Argentina
  • Australia
  • Bulgaria
  • Colombia
  • Croatia
  • Hungary
  • India
  • Japan
  • Lithuania
  • Malaysia
  • Mexico
  • New Zealand
  • Poland
  • Romania
  • Russia
  • Slovakia
  • South Africa
  • South Korea
  • Sri Lanka
  • Taiwan
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01202760 on ClinicalTrials.gov